SANOFI vs SPARC: Stock Comparison

SANOFI INDIA vs SUN PHARMA ADV.RES.CO.LTDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SANOFI INDIA is the larger company by market capitalisation. SANOFI INDIA shows a lower P/E, a higher dividend yield and lower leverage, while SUN PHARMA ADV.RES.CO.LTD shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SANOFI leads 5; SPARC leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SANOFISPARC

Valuation lens

What price are you paying?

Market CapContext only
₹7,275 Cr
₹6,482 Cr
P/E RatioSANOFI has the lower reading
0x
4.1x
P/B RatioSANOFI has the lower reading
0x
4.85x
EPSSANOFI has the higher reading
₹36.26
₹-0.65
Book ValueContext only
₹325.31
₹41.26
Dividend YieldSANOFI has the higher reading
3.96%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SANOFI is the larger company
₹7,275 Cr vs ₹6,482 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 4.1x
P/B Ratio
SANOFI has a lower P/B
0x vs 4.85x
EPS
SANOFI has higher earnings per share
₹36.26 vs ₹-0.65
Dividend Yield
SANOFI has a higher dividend yield
3.96% vs 0%
Revenue Growth (TTM YoY)
SPARC has faster revenue growth
6,716.8% vs -11.9%
EPS Growth (TTM YoY)
SPARC has faster EPS growth
0% vs -14.1%
Qtr Sales Growth
SPARC has stronger quarterly sales growth
0% vs -7.33%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSANOFISPARC
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSANOFISPARC
Live Price₹3,158.2₹199.47
Day Change-1.02%-1.52%
Volume9,8985.88 L
52-Week High₹5,175.5₹289
52-Week Low₹3,054₹108
Distance from 52W High-38.98%-30.98%

Valuation

MetricSANOFISPARC
Market Cap₹7,275 Cr₹6,482 Cr
P/E Ratio0x4.1x
P/B Ratio0x4.85x
EPS₹36.26₹-0.65
Book Value₹325.31₹41.26
Dividend Yield3.96%0%

Growth

MetricSANOFISPARC
Revenue Growth (TTM YoY)-11.9%6,716.8%
EPS Growth (TTM YoY)-14.1%0%
Qtr Sales Growth-7.33%0%
Qtr Profit Growth-18.62%-0.96%

Profitability & Leverage

MetricSANOFISPARC
ROE41.35%116.01%
ROCE64.11%83.81%
Net Margin19.26%82.65%
Operating Margin23.62%84.46%
Debt to Equity0x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSANOFISPARC
Promoter Holding0%65.67%
FII Holding5.69% 0.05 pp3.9% 1.86 pp
DII Holding19.87% 1.26 pp0.09% 0.79 pp
Public Holding14.04% 1.21 pp30.33% 1.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SANOFI INDIA and SUN PHARMA ADV.RES.CO.LTD.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.